GENENTA SCIENCE(SP.ADR)/1 - Asset Resilience Ratio
GENENTA SCIENCE(SP.ADR)/1 (K5F) has an Asset Resilience Ratio of 70.94% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See K5F working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how GENENTA SCIENCE(SP.ADR)/1's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see K5F total asset value.
Liquid Assets Composition Over Time
This chart breaks down GENENTA SCIENCE(SP.ADR)/1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of GENENTA SCIENCE(SP.ADR)/1 for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €22.62 Million | 70.94% |
| Total Liquid Assets | €22.62 Million | 70.94% |
Asset Resilience Insights
- Very High Liquidity: GENENTA SCIENCE(SP.ADR)/1 maintains exceptional liquid asset reserves at 70.94% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
GENENTA SCIENCE(SP.ADR)/1 Industry Peers by Asset Resilience Ratio
Compare GENENTA SCIENCE(SP.ADR)/1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for GENENTA SCIENCE(SP.ADR)/1 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for GENENTA SCIENCE(SP.ADR)/1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.94% | €22.62 Million ≈ $26.45 Million |
€31.89 Million ≈ $37.28 Million |
+16.44pp |
| 2024-12-31 | 54.49% | €8.08 Million ≈ $9.44 Million |
€14.82 Million ≈ $17.33 Million |
-13.01pp |
| 2023-12-31 | 67.50% | €15.08 Million ≈ $17.64 Million |
€22.35 Million ≈ $26.13 Million |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€33.44 Million ≈ $39.09 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€40.03 Million ≈ $46.80 Million |
-- |
About GENENTA SCIENCE(SP.ADR)/1
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more